Patients with schizophrenia can experience varying degrees of weight gain during medication treatment, which has become one of the important adverse effects of antipsychotic drugs. Weight gain is not only detrimental to patients’ physical health, but also has a great impact on patients’ psychological health, and is one of the important factors affecting treatment compliance. Therefore, weight gain has attracted increasing attention and focus. It has been reported in the literature that about 50% of patients experience significant weight gain after long-term use of typical and/or atypical antipsychotics. Common medications that tend to cause weight gain: clozapine, olanzapine, thioridazine, chlorpromazine, risperidone, haloperidol, and fluphenazine. Weight gain is associated with the strong 5-HT2. affinity of Hi and M3 receptors of the drug. Concomitant impaired glucolipid metabolism and triggering of type 2 diabetes with clozapine have been reported in several publications. When choosing a therapeutic agent, patients with weight problems or those with a family history of diabetes should choose an agent that has as little effect on body weight as possible. Weight gain in patients can be managed in the following ways